MX393976B - Inhibidores de muerte programada 1 (pd-19) /ligando de muerte programada 1 (pd-l1) para el tratamiento de cáncer. - Google Patents
Inhibidores de muerte programada 1 (pd-19) /ligando de muerte programada 1 (pd-l1) para el tratamiento de cáncer.Info
- Publication number
- MX393976B MX393976B MX2017010773A MX2017010773A MX393976B MX 393976 B MX393976 B MX 393976B MX 2017010773 A MX2017010773 A MX 2017010773A MX 2017010773 A MX2017010773 A MX 2017010773A MX 393976 B MX393976 B MX 393976B
- Authority
- MX
- Mexico
- Prior art keywords
- programmed death
- inhibitors
- cancer treatment
- ligand
- death ligand
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se relaciona con métodos para el tratamiento de cáncer en un paciente, que comprende administrar al paciente una cantidad terapéuticamente efectiva de un inhibidor de la interacción entre el receptor de PD-1 y su ligando PD-L1.
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562121025P | 2015-02-26 | 2015-02-26 | |
| US201562133721P | 2015-03-16 | 2015-03-16 | |
| US201562160291P | 2015-05-12 | 2015-05-12 | |
| US201562215394P | 2015-09-08 | 2015-09-08 | |
| US201562254424P | 2015-11-12 | 2015-11-12 | |
| PCT/US2016/019120 WO2016137985A1 (en) | 2015-02-26 | 2016-02-23 | Pd-1 / pd-l1 inhibitors for the treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017010773A MX2017010773A (es) | 2018-03-15 |
| MX393976B true MX393976B (es) | 2025-03-21 |
Family
ID=55588542
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017010773A MX393976B (es) | 2015-02-26 | 2016-02-23 | Inhibidores de muerte programada 1 (pd-19) /ligando de muerte programada 1 (pd-l1) para el tratamiento de cáncer. |
| MX2022001757A MX2022001757A (es) | 2015-02-26 | 2017-08-22 | Inhibidores de muerte programada 1 (pd-19)/ligando de muerte programada 1 (pd-l1) para el tratamiento de cancer. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022001757A MX2022001757A (es) | 2015-02-26 | 2017-08-22 | Inhibidores de muerte programada 1 (pd-19)/ligando de muerte programada 1 (pd-l1) para el tratamiento de cancer. |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US10800846B2 (es) |
| EP (2) | EP4279087A3 (es) |
| JP (3) | JP6885869B2 (es) |
| KR (1) | KR20170132171A (es) |
| CN (2) | CN107405401B (es) |
| AU (3) | AU2016222928B2 (es) |
| BR (1) | BR112017018234A2 (es) |
| CA (1) | CA2977767C (es) |
| IL (2) | IL278423B2 (es) |
| MX (2) | MX393976B (es) |
| NZ (1) | NZ733854A (es) |
| RU (1) | RU2714233C2 (es) |
| SG (2) | SG11201706918YA (es) |
| TW (2) | TWI755791B (es) |
| WO (1) | WO2016137985A1 (es) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112014012819B1 (pt) * | 2011-11-28 | 2022-08-16 | Merck Patent Gmbh | Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição |
| WO2015109391A1 (en) | 2014-01-24 | 2015-07-30 | Children's Hospital Of Eastern Ontario Research Institute Inc. | Smc combination therapy for the treatment of cancer |
| KR20170132171A (ko) | 2015-02-26 | 2017-12-01 | 메르크 파텐트 게엠베하 | 암 치료를 위한 pd1 / pdl1 저해제 |
| MA42971A (fr) | 2015-03-13 | 2018-08-15 | Cytomx Therapeutics Inc | Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation |
| RU2766890C2 (ru) | 2015-06-16 | 2022-03-16 | Мерк Патент Гмбх | Комбинированные способы лечения антагонистами pd-l1 |
| MX392711B (es) | 2015-08-11 | 2025-03-24 | Wuxi Biologics Ireland Ltd | Anticuerpos anti-pd-1 novedosos. |
| JP6869987B2 (ja) | 2015-09-01 | 2021-05-12 | アジェナス インコーポレイテッド | 抗pd−1抗体及びその使用方法 |
| DK3386541T3 (da) | 2015-12-07 | 2020-09-28 | Merck Patent Gmbh | Vandig farmaceutisk formulering omfattende anti-pd-1-antistof avelumab |
| CA3025391A1 (en) * | 2016-05-26 | 2017-11-30 | Merck Patent Gmbh | Pd-1 / pd-l1 inhibitors for cancer treatment |
| US11369618B2 (en) | 2016-06-17 | 2022-06-28 | The Trustees Of The University Of Pennsylvania | Compounds, compositions and methods for prevention and/or treatment of cancer |
| TN2019000081A1 (en) * | 2016-09-14 | 2020-07-15 | Beijing hanmi pharm co ltd | Antibody specifically binding to pd-1 and functional fragment thereof |
| BR112019006504A2 (pt) | 2016-10-06 | 2019-06-25 | Pfizer Inc. | regime de dosagem de avelumabe para o tratamento de câncer |
| WO2018098352A2 (en) | 2016-11-22 | 2018-05-31 | Jun Oishi | Targeting kras induced immune checkpoint expression |
| CN110300599B (zh) | 2016-12-07 | 2024-07-02 | 艾吉纳斯公司 | 抗体和其使用方法 |
| MA47509A (fr) * | 2017-02-16 | 2019-12-25 | Medimmune Llc | Traitement par anticorps anti-pd-l1 du cancer de la vessie |
| TW201834639A (zh) | 2017-03-06 | 2018-10-01 | 德商馬克專利公司 | 水性抗體調配物 |
| EP3372615A1 (en) | 2017-03-06 | 2018-09-12 | Merck Patent GmbH | Composition comprising avelumab |
| SG11201909064RA (en) * | 2017-03-30 | 2019-10-30 | Merck Patent Gmbh | Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer |
| CN110914302A (zh) | 2017-06-01 | 2020-03-24 | 赛托姆克斯治疗学股份有限公司 | 可活化抗pdl1抗体及其使用方法 |
| SG11202000387YA (en) | 2017-08-25 | 2020-03-30 | Five Prime Therapeutics Inc | B7-h4 antibodies and methods of use thereof |
| AU2018347331A1 (en) * | 2017-10-13 | 2020-04-09 | Merck Patent Gmbh | Combination of a PARP inhibitor and a PD-1 axis binding antagonist |
| US12668635B1 (en) | 2017-11-21 | 2026-06-30 | Arcus Biosciences, Inc. | Methods of treating solid tumors using an anti-PD-1 antibody or a fragment thereof |
| WO2019118855A1 (en) * | 2017-12-14 | 2019-06-20 | The Trustees Of The University Of Pennsylvania | Compounds and compositions for prevention and/or treatment of cancer |
| WO2019165077A1 (en) | 2018-02-21 | 2019-08-29 | Five Prime Therapeutics, Inc. | B7-h4 antibody formulations |
| WO2019180201A2 (en) * | 2018-03-22 | 2019-09-26 | Keires Ag | Antagonistic antigen binding proteins |
| CA3103245A1 (en) * | 2018-06-13 | 2019-12-19 | Merck Patent Gmbh | Treatment of stage iii nsclc and mitigation of pathological conditions associated with the treatment |
| CA3114024A1 (en) * | 2018-09-26 | 2020-04-02 | Merck Patent Gmbh | Combination of a pd-1 antagonist, an atr inhibitor and a platinating agent for the treatment of cancer |
| AU2019361923B2 (en) * | 2018-10-15 | 2026-07-09 | Five Prime Therapeutics, Inc. | Combination therapy for cancer |
| CA3119563A1 (en) * | 2018-11-14 | 2020-05-22 | Bayer Aktiengesellschaft | Pharmaceutical combination of anti-ceacam6 and either anti-pd-1 or anti-pd-l1 antibodies for the treatment of cancer |
| US11851490B2 (en) | 2019-08-15 | 2023-12-26 | Northwestern University | Methods and compositions for treating, inhibiting, and/or preventing heterotopic ossification |
| US20210169979A1 (en) * | 2019-12-05 | 2021-06-10 | The Board of Regents for the Oklahoma Agricultural and Mechanical Colleges | System and method for sonosensitized cancer immunotherapy with nanoparticles |
| MX2022008216A (es) * | 2020-01-02 | 2022-08-04 | Merck Sharp & Dohme Llc | Tratamiento de cancer en combinacion usando un antagonista de pd-1, un antagonista de ilt4 y lenvatinib o sales del mismo. |
| AU2020466790B2 (en) * | 2020-09-04 | 2025-07-10 | Pharma Mar, S.A. | Combination of lurbinectedin and immune checkpoint inhibitor |
| WO2023154799A1 (en) | 2022-02-14 | 2023-08-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Combination immunotherapy for treating cancer |
| TW202404634A (zh) * | 2022-04-05 | 2024-02-01 | 美商安進公司 | 胃癌的治療 |
| WO2024137442A1 (en) | 2022-12-21 | 2024-06-27 | Gilead Sciences, Inc. | Combination therapy for treating cancer |
Family Cites Families (107)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1000475A (en) | 1908-12-31 | 1911-08-15 | Rodney Robert Woodson | Coal-mining pick. |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| DE69233528T2 (de) | 1991-11-25 | 2006-03-16 | Enzon, Inc. | Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen |
| JPH07263576A (ja) | 1994-03-25 | 1995-10-13 | Hitachi Ltd | 半導体集積回路装置およびその製造方法 |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| CA2219361C (en) | 1995-04-27 | 2012-02-28 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| EP1972194A1 (en) | 1996-12-03 | 2008-09-24 | Amgen Fremont Inc. | Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom |
| WO1999029888A1 (en) | 1997-12-05 | 1999-06-17 | The Scripps Research Institute | Humanization of murine antibody |
| US7141581B2 (en) | 1999-07-02 | 2006-11-28 | Agouron Pharmaceuticals, Inc. | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use |
| TWI262914B (en) | 1999-07-02 | 2006-10-01 | Agouron Pharma | Compounds and pharmaceutical compositions for inhibiting protein kinases |
| US7794710B2 (en) * | 2001-04-20 | 2010-09-14 | Mayo Foundation For Medical Education And Research | Methods of enhancing T cell responsiveness |
| DE60334303D1 (de) | 2002-07-03 | 2010-11-04 | Tasuku Honjo | Immunpotenzierende zusammensetzungen |
| ES2367430T3 (es) | 2002-12-23 | 2011-11-03 | Wyeth Llc | Anticuerpos contra pd-1 y sus usos. |
| US7563869B2 (en) | 2003-01-23 | 2009-07-21 | Ono Pharmaceutical Co., Ltd. | Substance specific to human PD-1 |
| KR20050119671A (ko) | 2003-04-03 | 2005-12-21 | 화이자 인코포레이티드 | Ag013736을 포함하는 제형 |
| AR045563A1 (es) | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
| ES2689328T3 (es) | 2004-01-07 | 2018-11-13 | Novartis Vaccines And Diagnostics, Inc. | Anticuerpo monoclonal M-CSF-específico y usos del mismo |
| CN101052633A (zh) | 2004-11-02 | 2007-10-10 | 辉瑞大药厂 | 制备吲唑化合物的方法 |
| BRPI0517921A (pt) | 2004-11-02 | 2008-10-21 | Pfizer | métodos para preparar compostos de indazol |
| CN101094836A (zh) | 2004-11-02 | 2007-12-26 | 辉瑞大药厂 | 制备吲唑化合物的方法 |
| JP2008518900A (ja) | 2004-11-02 | 2008-06-05 | ファイザー・インク | インダゾール化合物の調製方法 |
| KR20070060145A (ko) | 2004-11-02 | 2007-06-12 | 화이자 인코포레이티드 | 6-[2-(메틸카바모일)페닐설파닐]-3-e-[2-(피리딘-2-일)에테닐]인다졸의 다형체 형태 |
| EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| US20080274192A1 (en) | 2005-05-19 | 2008-11-06 | Pfizer Inc. | Pharmaceutical Compositions Comprising an Amorphous Form of a Vegf-R-Inhibitor |
| KR101704734B1 (ko) * | 2005-07-01 | 2017-02-09 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| US20100055111A1 (en) | 2007-02-14 | 2010-03-04 | Med. College Of Georgia Research Institute, Inc. | Indoleamine 2,3-dioxygenase, pd-1/pd-l pathways, and ctla4 pathways in the activation of regulatory t cells |
| CN101679356A (zh) | 2007-04-05 | 2010-03-24 | 辉瑞产品公司 | 适用于治疗哺乳动物异常细胞生长的6-[2-(甲基-氨甲酰基)苯基硫基]-3-e-[2-(吡啶-2-基)乙烯基]吲唑的晶型 |
| PT2170959E (pt) | 2007-06-18 | 2014-01-07 | Merck Sharp & Dohme | Anticorpos para o receptor humano de morte programada pd-1 |
| SI2242771T1 (sl) | 2007-12-14 | 2013-09-30 | Bristol-Myers Squibb Company | Vezane molekule k humanemu ox40 receptorju |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| WO2010098788A2 (en) | 2008-08-25 | 2010-09-02 | Amplimmune, Inc. | Pd-i antagonists and methods for treating infectious disease |
| EA201500417A1 (ru) * | 2008-08-25 | 2015-11-30 | Эмплиммьюн, Инк. | Композиции антагонистов pd-1 и способы применения |
| WO2010036959A2 (en) | 2008-09-26 | 2010-04-01 | Dana-Farber Cancer Institute | Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor |
| US8563735B2 (en) | 2008-12-05 | 2013-10-22 | Abbvie Inc. | Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
| MX356367B (es) | 2008-12-09 | 2018-05-25 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t. |
| WO2010089411A2 (en) | 2009-02-09 | 2010-08-12 | Universite De La Mediterranee | Pd-1 antibodies and pd-l1 antibodies and uses thereof |
| EP3279215B1 (en) | 2009-11-24 | 2020-02-12 | MedImmune Limited | Targeted binding agents against b7-h1 |
| EP2504028A4 (en) | 2009-11-24 | 2014-04-09 | Amplimmune Inc | SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2 |
| CN102892786B (zh) | 2010-03-11 | 2016-03-16 | Ucb医药有限公司 | Pd-1抗体 |
| SG10201408229WA (en) | 2010-08-31 | 2015-02-27 | Genentech Inc | Biomarkers and methods of treatment |
| NZ729044A (en) | 2010-09-09 | 2020-07-31 | Pfizer | 4-1bb binding molecules |
| DK2714738T3 (en) | 2011-05-24 | 2019-01-28 | Zyngenia Inc | MULTIVALENT AND MONOVALENT MULTISPECIFIC COMPLEXES AND THEIR APPLICATIONS |
| BR112014002353B1 (pt) | 2011-08-01 | 2022-09-27 | Genentech, Inc | Usos de antagonistas de ligação do eixo pd-1 e inibidores de mek, composições farmacêuticas, e kit |
| JP6038920B2 (ja) | 2011-08-23 | 2016-12-07 | ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム | 抗ox40抗体およびそれを使用する方法 |
| TW201531309A (zh) | 2011-09-30 | 2015-08-16 | Pfizer | N-甲基-2-〔3-((e)-2-吡啶-2-基-乙烯基)-1h-吲唑-6-基硫烷基〕苯甲醯胺之藥學組成物 |
| JP2014533262A (ja) | 2011-11-11 | 2014-12-11 | ファイザー・インク | 慢性骨髄性白血病を治療するためのn−メチル−2−[3−((e)−2−ピリジン−2−イル−ビニル)−1h−インダゾール−6−イルスルファニル]−ベンズアミド |
| BR112014012819B1 (pt) | 2011-11-28 | 2022-08-16 | Merck Patent Gmbh | Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição |
| US9828432B2 (en) | 2012-02-06 | 2017-11-28 | Providence Health & Services—Oregon | Cancer treatment and monitoring methods using OX40 agonists |
| PL2844282T3 (pl) | 2012-05-04 | 2019-11-29 | Pfizer | Antygeny związane z gruczołem krokowym i schematy immunoterapii oparte na szczepionce |
| US9856320B2 (en) * | 2012-05-15 | 2018-01-02 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting PD-1/PD-L1 signaling |
| ES2742379T3 (es) | 2012-05-31 | 2020-02-14 | Hoffmann La Roche | Procedimientos de tratamiento del cáncer usando antagonistas de unión al eje de PD-1 y antagonistas de VEGF |
| US9682143B2 (en) | 2012-08-14 | 2017-06-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
| BR112015007184A2 (pt) * | 2012-10-02 | 2017-08-08 | Bristol Myers Squibb Co | combinação de anticorpos anti-kir e anticorpos anti-pd-1 para tratar câncer |
| AR093984A1 (es) | 2012-12-21 | 2015-07-01 | Merck Sharp & Dohme | Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano |
| KR20150131269A (ko) | 2013-03-15 | 2015-11-24 | 제넨테크, 인크. | Pd-1 및 pd-l1 관련 상태를 치료하기 위한 바이오마커 및 방법 |
| CN105073128A (zh) | 2013-04-03 | 2015-11-18 | Ibc药品公司 | 用于诱导对疾病的免疫应答的组合疗法 |
| AU2014253090B2 (en) | 2013-04-12 | 2018-10-25 | Morphosys Ag | Antibodies targeting M-CSF |
| DE102013008118A1 (de) | 2013-05-11 | 2014-11-13 | Merck Patent Gmbh | Arylchinazoline |
| IL321966A (en) | 2013-09-11 | 2025-09-01 | Medimmune Ltd | Anti-B7-H1 antibodies for tumor treatment |
| AR097584A1 (es) | 2013-09-12 | 2016-03-23 | Hoffmann La Roche | Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano |
| US10202454B2 (en) | 2013-10-25 | 2019-02-12 | Dana-Farber Cancer Institute, Inc. | Anti-PD-L1 monoclonal antibodies and fragments thereof |
| EA201690912A1 (ru) * | 2013-11-05 | 2016-10-31 | Когнейт Биосервисис, Инк. | Комбинации ингибиторов контрольных точек и терапевтических средств для лечения рака |
| US9457019B2 (en) | 2013-11-07 | 2016-10-04 | Deciphera Pharmaceuticals, Llc | Methods for inhibiting tie-2 kinase useful in the treatment of cancer |
| AU2013404949B2 (en) | 2013-11-07 | 2018-10-18 | Deciphera Pharmaceuticals, Llc | Methods for inhibiting TIE2 kinase useful in the treatment of cancer |
| US20160303231A1 (en) | 2013-12-11 | 2016-10-20 | Robert Iannone | Treating cancer with a combination of a pd-1 antagonist and a vegfr inhibitor |
| US20150210772A1 (en) | 2013-12-17 | 2015-07-30 | Genentech, Inc. | Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody |
| MX2016007965A (es) | 2013-12-17 | 2016-10-28 | Genentech Inc | Terapia de combinacion que comprende agonistas de union a ox40 y antagonistas de union al eje pd-1. |
| ES2763429T5 (es) | 2013-12-17 | 2023-06-21 | Hoffmann La Roche | Procedimientos de tratamiento de cánceres usando antagonistas de la unión al eje de PD-1 y taxanos |
| US9045545B1 (en) * | 2014-07-15 | 2015-06-02 | Kymab Limited | Precision medicine by targeting PD-L1 variants for treatment of cancer |
| UA122479C2 (uk) | 2014-01-24 | 2020-11-25 | Дана-Фарбер Кенсер Інстітьют, Інк. | Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1) |
| US10570202B2 (en) | 2014-02-04 | 2020-02-25 | Pfizer Inc. | Combination of a PD-1 antagonist and a VEGFR inhibitor for treating cancer |
| EP3107538B1 (en) | 2014-02-18 | 2020-05-27 | Health Research, Inc. | Combination therapy for hepatocellular carcinoma |
| EP3114144A1 (en) | 2014-03-05 | 2017-01-11 | Bristol-Myers Squibb Company | Treatment of renal cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent |
| JP2017515859A (ja) | 2014-05-15 | 2017-06-15 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | 抗pd−1抗体と他の抗癌剤の組み合わせを使用する肺癌の処置 |
| CN106604933B (zh) * | 2014-07-11 | 2021-08-10 | 文塔纳医疗系统公司 | 抗pd-l1抗体及其诊断用途 |
| US10517875B2 (en) | 2014-07-23 | 2019-12-31 | Mayo Foundation for Medical Engineering and Research | Targeting DNA-PKcs and B7-H1 to treat cancer |
| US9539245B2 (en) | 2014-08-07 | 2017-01-10 | Aerpio Therapeutics, Inc. | Combination of immunotherapies with activators of Tie-2 |
| US10695426B2 (en) | 2014-08-25 | 2020-06-30 | Pfizer Inc. | Combination of a PD-1 antagonist and an ALK inhibitor for treating cancer |
| EP3191126B1 (en) | 2014-09-13 | 2020-05-13 | Novartis AG | Combination therapies of alk inhibitors |
| KR20170066546A (ko) | 2014-10-03 | 2017-06-14 | 노파르티스 아게 | 조합 요법 |
| SG11201702401RA (en) * | 2014-10-14 | 2017-04-27 | Novartis Ag | Antibody molecules to pd-l1 and uses thereof |
| WO2016059602A2 (en) | 2014-10-16 | 2016-04-21 | Glaxo Group Limited | Methods of treating cancer and related compositions |
| HUE054012T2 (hu) * | 2014-10-29 | 2021-08-30 | Five Prime Therapeutics Inc | Kombinációs terápia rák ellen |
| CN106999583A (zh) | 2014-11-17 | 2017-08-01 | 豪夫迈·罗氏有限公司 | 包含ox40结合激动剂和pd‑1轴结合拮抗剂的组合疗法 |
| CA2968680A1 (en) | 2014-12-02 | 2016-06-09 | Celgene Corporation | Combination therapies |
| GB201421647D0 (en) | 2014-12-05 | 2015-01-21 | Amcure Gmbh And Ruprecht-Karls-Universitat And Karlsruher Institut F�R Technologie | CD44v6-derived cyclic peptides for treating cancers and angiogenesis related diseases |
| TWI595006B (zh) | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗pd-1抗體類和使用彼等之方法 |
| EP3233918A1 (en) | 2014-12-19 | 2017-10-25 | Novartis AG | Combination therapies |
| KR20170132171A (ko) | 2015-02-26 | 2017-12-01 | 메르크 파텐트 게엠베하 | 암 치료를 위한 pd1 / pdl1 저해제 |
| RU2766890C2 (ru) | 2015-06-16 | 2022-03-16 | Мерк Патент Гмбх | Комбинированные способы лечения антагонистами pd-l1 |
| JP2018529719A (ja) | 2015-09-30 | 2018-10-11 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | Alk陰性がんを処置するためのpd−1系結合アンタゴニストおよびalk阻害剤の組合せ |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Hdac抑制劑與pd-l1抑制劑之組合治療 |
| CA3025391A1 (en) | 2016-05-26 | 2017-11-30 | Merck Patent Gmbh | Pd-1 / pd-l1 inhibitors for cancer treatment |
| BR112019006504A2 (pt) | 2016-10-06 | 2019-06-25 | Pfizer Inc. | regime de dosagem de avelumabe para o tratamento de câncer |
| SG11201909064RA (en) * | 2017-03-30 | 2019-10-30 | Merck Patent Gmbh | Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer |
-
2016
- 2016-02-23 KR KR1020177026975A patent/KR20170132171A/ko not_active Ceased
- 2016-02-23 EP EP23193773.1A patent/EP4279087A3/en not_active Withdrawn
- 2016-02-23 RU RU2017133273A patent/RU2714233C2/ru active
- 2016-02-23 AU AU2016222928A patent/AU2016222928B2/en not_active Ceased
- 2016-02-23 CA CA2977767A patent/CA2977767C/en active Active
- 2016-02-23 NZ NZ733854A patent/NZ733854A/en not_active IP Right Cessation
- 2016-02-23 WO PCT/US2016/019120 patent/WO2016137985A1/en not_active Ceased
- 2016-02-23 BR BR112017018234A patent/BR112017018234A2/pt not_active Application Discontinuation
- 2016-02-23 MX MX2017010773A patent/MX393976B/es unknown
- 2016-02-23 SG SG11201706918YA patent/SG11201706918YA/en unknown
- 2016-02-23 CN CN201680012312.1A patent/CN107405401B/zh not_active Expired - Fee Related
- 2016-02-23 SG SG10201810615VA patent/SG10201810615VA/en unknown
- 2016-02-23 EP EP16711389.3A patent/EP3262073A1/en not_active Withdrawn
- 2016-02-23 CN CN202011179277.7A patent/CN112263677A/zh active Pending
- 2016-02-23 US US15/553,437 patent/US10800846B2/en active Active
- 2016-02-23 IL IL278423A patent/IL278423B2/en unknown
- 2016-02-23 JP JP2017545299A patent/JP6885869B2/ja not_active Expired - Fee Related
- 2016-02-26 TW TW109124450A patent/TWI755791B/zh not_active IP Right Cessation
- 2016-02-26 TW TW105106010A patent/TWI748942B/zh not_active IP Right Cessation
-
2017
- 2017-08-22 MX MX2022001757A patent/MX2022001757A/es unknown
- 2017-08-24 IL IL254131A patent/IL254131B/en active IP Right Grant
-
2020
- 2020-03-23 JP JP2020050850A patent/JP7116113B2/ja not_active Expired - Fee Related
- 2020-08-05 US US16/985,805 patent/US20200362040A1/en not_active Abandoned
-
2021
- 2021-06-22 AU AU2021204211A patent/AU2021204211A1/en not_active Abandoned
- 2021-06-22 AU AU2021204217A patent/AU2021204217A1/en not_active Abandoned
- 2021-06-29 JP JP2021107909A patent/JP2021178822A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022001757A (es) | Inhibidores de muerte programada 1 (pd-19)/ligando de muerte programada 1 (pd-l1) para el tratamiento de cancer. | |
| MX2018014435A (es) | Inhibidores de muerte programada 1 (pd-1) ligando de muerte programada (pd-l1) para el tratamiento de cancer. | |
| MX376078B (es) | Combinación de un antagonista de pd -1 y dinaciclib para usarse en el tratamiento de cáncer. | |
| MX2020013649A (es) | Composiciones y metodos para inhibir la actividad de la arginasa. | |
| EA201891057A1 (ru) | Композиции и способы для ингибирования активности аргиназы | |
| PH12017500070A1 (en) | Methods of treating cancer using tigit inhibitors and anti-cancer agents | |
| EA201691376A1 (ru) | Комбинация антагониста pd-1 и ингибитора vegfr для лечения рака | |
| BR112018073328A2 (pt) | combinação, composição farmacêutica, kit, método para tratamento de câncer, método para a redução de um nível de células, método para reduzir o nível de células, método para aumentar a atividade, método para aumentar a citotoxicidade | |
| PH12016501550B1 (en) | Combination of a pd-1 antagonist and an ido1 inhibitor for treating cancer | |
| PH12016502179A1 (en) | Inhibitors of lysine specific demethylase-1 | |
| PH12016500511A1 (en) | Selective grp94 inhibitors and uses thereof | |
| EA201891340A1 (ru) | Лечение рака с использованием 2-дезокси-2-фтор-l-фукозы в комбинации с ингибитором контрольных точек | |
| BR112019001398A2 (pt) | métodos para tratamento de câncer de próstata | |
| HK1256042A1 (zh) | 用於治疗糖尿病周围神经病变的hdac抑制剂 | |
| MX394452B (es) | Inhibicion de la actividad de olig2. | |
| MX390320B (es) | Farmaco de combinacion. | |
| ZA201901367B (en) | Inhibition of olig2 activity | |
| EA201991517A1 (ru) | Композиции и способы ингибирования активности аргиназы | |
| JOP20180038A1 (ar) | مثبطات pd-1/pd-l1 | |
| EA202191138A1 (ru) | Композиции и способы для ингибирования активности аргиназы |